[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406331-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406331-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","psma-petct-in-castration-resistant-prostate-cancer-myth-or-reality","PSMA PET/CT in Castration-Resistant Prostate Cancer - Myth or Reality","","PSMA ligand PET has been incorporated into international guidelines for multiple prostate cancer indications, but its role in castration-resistant prostate cancer (CRPC) remains uncertain. This review evaluates the clinical value of PSMA PET/CT in CRPC, highlighting improved detection rates versus conventional imaging and fewer M0 CRPC cases. Prognostic impact is still unresolved, and sensitivity/specificity limitations persist, including clonal heterogeneity, unspecific bone uptake, and second primary neoplasms. Multi-tracer assessment with PSMA and [18F]FDG PET plus multidisciplinary review may enable more precise evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/psma-petct-in-castration-resistant-prostate-cancer-myth-or-reality/406331/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/psma-petct-in-castration-resistant-prostate-cancer-myth-or-reality/406331.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does PSMA ligand PET/CT compare with conventional imaging in CRPC detection?","Question",{"text":63,"@type":64},"PSMA ligand PET shows higher detection rates than conventional imaging and can significantly reduce the number of M0 CRPC patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the main limitations of PSMA PET in CRPC regarding accuracy?",{"text":68,"@type":64},"The review notes sensitivity and specificity limitations driven by CRPC heterogeneity, including potential PSMA-negative or PSMA-positive clones, along with unspecific bone uptake and second primary neoplasms expressing PSMA.",{"name":70,"@type":61,"acceptedAnswer":71},"How can clinicians improve evaluation of CRPC patients using PSMA PET/CT?",{"text":72,"@type":64},"Combining PSMA ligand imaging with [18F]FDG PET in integrated multi-tracer approaches, together with multidisciplinary discussion, supports more accurate patient assessment from a precision medicine perspective.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406331,1790765384,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of  \nClinical Medicine  \nReview  \nPSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?  \nLuca Urso 1,†, Luca Filippi 2,†, Angelo Castello 3,*, Maria Cristina Marzola 1, Mirco Bartolomei 4, Corrado Cittanti 4,5, Luigia Florimonte 3, Massimo Castellani 3, Paolo Zucali 6,7, Alessio Bruni 8, Roberto Sabbatini 9, Massimo Dominici 9, Stefano Panareo 10,‡ and Laura Evangelista 6,11,‡  \nCitation: Urso, L.; Filippi, L.;  \nCastello, A.; Marzola, M.C.;  \nBartolomei, M.; Cittanti, C.; Florimonte, L.; Castellani, M.; Zucali, P.; Bruni, A.; et al. PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? J. Clin. Med. 2023, 12, 7130. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)jcm12227130  \nAcademic Editors: Arutselvan Natarajan and Ryogo Minamimoto  \nReceived: 25 September 2023  \nRevised: 25 October 2023  \nAccepted: 14 November 2023  \nPublished: 16 November 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Nuclear Medicine—PET/CT Center, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy; [luca.urso@unife.it](luca.urso@unife.it) (L.U.); [mariacristina.marzola@aulss5.veneto.it](mariacristina.marzola@aulss5.veneto.it) (M.C.M.)  \n2 Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV, Policlinico Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy; luca.filippi@ptvonline.it  \n3 Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; luigia.fl[orimonte@policlinico.mi.it](orimonte@policlinico.mi.it) (L.F.); [massimo.castellani@policlinico.mi.it](massimo.castellani@policlinico.mi.it) (M.C.)  \n4 Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, 44124 Ferrara, Italy; [m.bartolomei@ospfe.it](m.bartolomei@ospfe.it) (M.B.); [ctc@unife.it](ctc@unife.it) (C.C.)  \n5 Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy  \n6 Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Milan, Italy; [paolo.zucali@hunimed.eu](paolo.zucali@hunimed.eu) (P.Z.); [laura.evangelista@hunimed.eu](laura.evangelista@hunimed.eu) (L.E.)  \n7 Department of Oncology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy  \n8 Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena,  \n41124 Modena, Italy; [bruni.alessio@aou.mo.it](bruni.alessio@aou.mo.it)  \n9 Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Via del Pozzo 71, 41124 Modena, Italy; [sabbatini@unimore.it](sabbatini@unimore.it) (R.S.); [dominici.massimo@aou.mo.it](dominici.massimo@aou.mo.it) (M.D.)  \n10 Nuclear Medicine Unit, Department of Oncology and Hematology, University Hospital of Modena, Via del Pozzo 71, 41124 Modena, Italy; [panareo.stefano@aou.mo.it](panareo.stefano@aou.mo.it)  \n11 Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy  \n* Correspondence: [angelo.castello@policlinico.mi.it](angelo.castello@policlinico.mi.it)  \n† These authors contributed equally to this work and they are co-first authors.  \n‡ These authors contributed equally to this work and they are co-senior authors.  \nAbstract: Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC) . The aim of this work is to assess the clinical value of PSMA ligand PET/CT in patients with CR","cbCailgy87UQ0l5m","https://ap.wps.com/l/cbCailgy87UQ0l5m","pdf",1465734,14,"English","# Abstract\n# Keywords\n# Introduction\n## Castration-resistant prostate cancer (CRPC) overview\n## Clinical subtypes and imaging distinction","[{\"question\":\"How does PSMA ligand PET/CT compare with conventional imaging in CRPC detection?\",\"answer\":\"PSMA ligand PET shows higher detection rates than conventional imaging and can significantly reduce the number of M0 CRPC patients.\"},{\"question\":\"What are the main limitations of PSMA PET in CRPC regarding accuracy?\",\"answer\":\"The review notes sensitivity and specificity limitations driven by CRPC heterogeneity, including potential PSMA-negative or PSMA-positive clones, along with unspecific bone uptake and second primary neoplasms expressing PSMA.\"},{\"question\":\"How can clinicians improve evaluation of CRPC patients using PSMA PET/CT?\",\"answer\":\"Combining PSMA ligand imaging with [18F]FDG PET in integrated multi-tracer approaches, together with multidisciplinary discussion, supports more accurate patient assessment from a precision medicine perspective.\"}]","PSMA PET/CT in Castration-Resistant Prostate Cancer - Myth or Reality | PDF",1790564881,35]